These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 20393432)

  • 1. Treating restless legs syndrome with rotigotine.
    Reading P
    Br J Hosp Med (Lond); 2010 Apr; 71(4):216-9. PubMed ID: 20393432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rotigotine and restless legs syndrome: new indication. The worst dopamine agonist. Just as unsatisfactory; defective design.
    Prescrire Int; 2009 Oct; 18(103):197. PubMed ID: 19882782
    [No Abstract]   [Full Text] [Related]  

  • 3. Rotigotine for restless legs syndrome.
    Davies S
    Drugs Today (Barc); 2009 Sep; 45(9):663-8. PubMed ID: 19956807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.
    Bogan RK
    Clin Ther; 2014 Mar; 36(3):436-55. PubMed ID: 24636821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Another dopamine agonist for treatment of restless legs syndrome.
    Earley CJ
    Lancet Neurol; 2011 Aug; 10(8):675-7. PubMed ID: 21705274
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial.
    Trenkwalder C; Benes H; Poewe W; Oertel WH; Garcia-Borreguero D; de Weerd AW; Ferini-Strambi L; Montagna P; Odin P; Stiasny-Kolster K; Högl B; Chaudhuri KR; Partinen M; Schollmayer E; Kohnen R;
    Lancet Neurol; 2008 Jul; 7(7):595-604. PubMed ID: 18515185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restless legs syndrome sees the light of day.
    Sethi KD
    Lancet Neurol; 2008 Jul; 7(7):564-5. PubMed ID: 18515184
    [No Abstract]   [Full Text] [Related]  

  • 8. Rotigotine transdermal delivery for the treatment of restless legs syndrome.
    Sixel-Döring F; Trenkwalder C
    Expert Opin Pharmacother; 2010 Mar; 11(4):649-56. PubMed ID: 20163275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology and efficacy of rotigotine (Neupro® patch) in the treatment of restless leg syndrome.
    Ferini-Strambi L; Marelli S; Galbiati A
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):967-75. PubMed ID: 27224246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rotigotine Transdermal Patch: A Review in Restless Legs Syndrome.
    Garnock-Jones KP
    Drugs; 2016 Jul; 76(10):1031-40. PubMed ID: 27324269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation.
    Winkelman JW; Mackie SE; Mei LA; Platt S; Schoerning L
    Sleep Med; 2016 Aug; 24():18-23. PubMed ID: 27810181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rotigotine Schwarz Pharma.
    Mucke HA
    IDrugs; 2003 Sep; 6(9):894-9. PubMed ID: 12964070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
    Splinter MY
    Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rotigotine. One patch, two targets!].
    Sabourin G
    Perspect Infirm; 2013; 10(4):60. PubMed ID: 24046901
    [No Abstract]   [Full Text] [Related]  

  • 15. Post Hoc Analysis of Data from Two Clinical Trials Evaluating the Minimal Clinically Important Change in International Restless Legs Syndrome Sum Score in Patients with Restless Legs Syndrome (Willis-Ekbom Disease).
    Ondo WG; Grieger F; Moran K; Kohnen R; Roth T
    J Clin Sleep Med; 2016 Jan; 12(1):63-70. PubMed ID: 26446245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of rotigotine on daytime symptoms in patients with primary restless legs syndrome: a randomized, placebo-controlled study.
    Garcia-Borreguero D; Allen R; Hudson J; Dohin E; Grieger F; Moran K; Schollmayer E; Smit R; Winkelman J
    Curr Med Res Opin; 2016; 32(1):77-85. PubMed ID: 26569149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease.
    Zareba G
    Drugs Today (Barc); 2006 Jan; 42(1):21-8. PubMed ID: 16511608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta-analysis.
    Iftikhar IH; Alghothani L; Trotti LM
    Eur J Neurol; 2017 Dec; 24(12):1446-1456. PubMed ID: 28888061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of rotigotine on clinical symptoms, quality of life and sleep hygiene adequacy in haemodialysis-associated restless legs syndrome.
    Esteve V; Carneiro J; Salazar G; Pou M; Tapia I; Fulquet M; Duarte V; Saurina A; Moreno F; Ramírez de Arellano M
    Nefrologia (Engl Ed); 2018; 38(1):79-86. PubMed ID: 29198453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome.
    Kenney C; Jankovic J
    Expert Opin Pharmacother; 2007 Jun; 8(9):1329-35. PubMed ID: 17563266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.